{
    "nctId": "NCT02955940",
    "briefTitle": "An Open-Label Study to Enable Continued Treatment Access for Subjects Previously Enrolled in Studies of Ruxolitinib",
    "officialTitle": "An Open-Label, Multicenter, Rollover Study to Enable Continued Treatment Access for Subjects Previously Enrolled in Studies of Ruxolitinib",
    "overallStatus": "ACTIVE_NOT_RECRUITING",
    "conditions": "Pancreatic Cancer, Colorectal Cancer (CRC), Breast Cancer, Lung Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE2",
    "allocation": "NON_RANDOMIZED",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 10,
    "primaryOutcomeMeasure": "Frequency and types of adverse events and serious adverse events",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Currently enrolled and receiving treatment in an Incyte-sponsored clinical study of ruxolitinib that has completed or been terminated.\n* Currently tolerating treatment in the parent protocol.\n* Currently benefiting from the treatment with ruxolitinib alone, ruxolitinib plus background cancer therapy, or background cancer therapy alone, as determined by the investigator.\n* Have at least stable disease, as determined by the investigator.\n* Has demonstrated compliance, as assessed by the investigator, with the parent study protocol requirements.\n\nExclusion Criteria:\n\n* Has been permanently discontinued from study treatment in the parent study for any reason.\n* Able to access ruxolitinib and/or background cancer therapy outside of the clinical study.",
    "sex": "ALL",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}